Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme Academic Article Article uri icon

Overview

MeSH Major

  • Brain
  • Nerve Regeneration
  • Neurons
  • Stem Cell Transplantation
  • Stem Cells

abstract

  • In this prospective Phase III study, no survival or PFS benefit was seen with accelerated hyperfractionated irradiation to 70.4 Gy, nor was any benefit seen with DFMO as a radiosensitizer. Standard fractionated irradiation to 59.4 Gy remains the treatment of choice for newly diagnosed patients with glioblastoma multiforme.

publication date

  • January 2001

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0360-3016(00)01458-9

PubMed ID

  • 11163499

Additional Document Info

start page

  • 71

end page

  • 7

volume

  • 49

number

  • 1